Tuesday, 19 August 2008 09:13 AM
At the Company's AGM held on the 31st July, the following directors were re-appointed for the ensuing year: Wayne Christensen, Carol Leacy and John Mason.
The following new Directors were appointed, Michael Hoole, Dr. Bryan Simmons and Bryan Tassin, to comprise a board of six directors.
Subsequent to the AGM, resignations have been received from Wayne Christensen, Carol Leacy and Michael Hoole.
The remaining Directors have, in accordance with the provisions of the Company's Articles, filled the vacancies with Ronald Bayne, Paul Frigstad and David Mason - the replacement Directors have considerable experience in the Company's affairs and the development of Specific Antibodies and have filed their consent to act at the Company's registered offices.
About IRI Separation Technologies Inc.
IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of polyclonal immunoglobulin antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from chicken eggs. The immunoglobulin antibodies are intended for both the general and specific antibody market.
SOURCE: IRI Separation Technologies Inc.
IRI Separation Technologies Inc. - Investor Relations
Paul Frigstad
Manager of Investor Relations
(604) 929-7332
1-888-822-9231 (FAX)
Email: [email protected]
IRI Separation Technologies Inc.
R Bayne
President
(778) 241-4869
(604) 854-6599 (FAX)
Email: [email protected]
Website: www.iriseparation.com